93 related articles for article (PubMed ID: 12669474)
1. Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research.
Kennett RH
Curr Opin Mol Ther; 2003 Feb; 5(1):70-5. PubMed ID: 12669474
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.
Bleumer I; Knuth A; Oosterwijk E; Hofmann R; Varga Z; Lamers C; Kruit W; Melchior S; Mala C; Ullrich S; De Mulder P; Mulders PF; Beck J
Br J Cancer; 2004 Mar; 90(5):985-90. PubMed ID: 14997194
[TBL] [Abstract][Full Text] [Related]
3. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.
Brouwers AH; Buijs WC; Oosterwijk E; Boerman OC; Mala C; De Mulder PH; Corstens FH; Mulders PF; Oyen WJ
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3953S-60S. PubMed ID: 14506194
[TBL] [Abstract][Full Text] [Related]
4. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.
Surfus JE; Hank JA; Oosterwijk E; Welt S; Lindstrom MJ; Albertini MR; Schiller JH; Sondel PM
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):184-91. PubMed ID: 8811493
[TBL] [Abstract][Full Text] [Related]
5. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma.
Oosterwijk E; Debruyne FM; Schalken JA
Semin Oncol; 1995 Feb; 22(1):34-41. PubMed ID: 7855618
[No Abstract] [Full Text] [Related]
6. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.
Steffens MG; Boerman OC; de Mulder PH; Oyen WJ; Buijs WC; Witjes JA; van den Broek WJ; Oosterwijk-Wakka JC; Debruyne FM; Corstens FH; Oosterwijk E
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3268s-3274s. PubMed ID: 10541374
[TBL] [Abstract][Full Text] [Related]
7. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy.
Steffens MG; Boerman OC; Oyen WJ; Kniest PH; Witjes JA; Oosterhof GO; van Leenders GJ; Debruyne FM; Corstens FH; Oosterwijk E
Cancer Res; 1999 Apr; 59(7):1615-9. PubMed ID: 10197637
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response.
Brouwers AH; Buijs WC; Mulders PF; de Mulder PH; van den Broek WJ; Mala C; Oosterwijk E; Boerman OC; Corstens FH; Oyen WJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7178s-7186s. PubMed ID: 16203819
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.
Leigh BR; Burke PA; Hong AM; O'Donnell RT; Howell LP; Miers LA; DeNardo GL; DeNardo SJ
Cancer Biother Radiopharm; 1999 Apr; 14(2):113-9. PubMed ID: 10850294
[TBL] [Abstract][Full Text] [Related]
11. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients.
Loh A; Sgouros G; O'Donoghue JA; Deland D; Puri D; Capitelli P; Humm JL; Larson SM; Old LJ; Divgi CR
J Nucl Med; 1998 Mar; 39(3):484-9. PubMed ID: 9529296
[TBL] [Abstract][Full Text] [Related]
13. Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute.
Sheikh N
Curr Opin Mol Ther; 2003 Aug; 5(4):428-32. PubMed ID: 14513687
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeled monoclonal antibody G250 in renal-cell carcinoma.
Oosterwijk E; Debruyne FM
World J Urol; 1995; 13(3):186-90. PubMed ID: 7550393
[TBL] [Abstract][Full Text] [Related]
15. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma.
Bleumer I; Oosterwijk E; Oosterwijk-Wakka JC; Völler MC; Melchior S; Warnaar SO; Mala C; Beck J; Mulders PF
J Urol; 2006 Jan; 175(1):57-62. PubMed ID: 16406869
[TBL] [Abstract][Full Text] [Related]
16. Improving the efficacy of antibody-based cancer therapies.
Carter P
Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
[TBL] [Abstract][Full Text] [Related]
17. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250.
Steffens MG; Boerman OC; Oosterwijk-Wakka JC; Oosterhof GO; Witjes JA; Koenders EB; Oyen WJ; Buijs WC; Debruyne FM; Corstens FH; Oosterwijk E
J Clin Oncol; 1997 Apr; 15(4):1529-37. PubMed ID: 9193349
[TBL] [Abstract][Full Text] [Related]
18. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts.
Kranenborg MH; Boerman OC; de Weijert MC; Oosterwijk-Wakka JC; Corstens FH; Oosterwijk E
Cancer; 1997 Dec; 80(12 Suppl):2390-7. PubMed ID: 9406688
[TBL] [Abstract][Full Text] [Related]
19. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
20. Engineering mouse monoclonal antibodies for cancer immunotherapy.
Orlandi R
Year Immunol; 1993; 7():69-73. PubMed ID: 8372514
[No Abstract] [Full Text] [Related]
[Next] [New Search]
